Patent · US Active

Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor VIII

US9511123B2 · kind B2 · utility

0Cited by

2References

5Claims

0Family size

Assignee

CSL Behring AG · DE

Inventors

Sabine Zollner · Muri, CH
Hubert Metzner · Marburg, DE

Key dates

Filing date	Oct 18, 2012
Grant date	Dec 6, 2016
Priority date	—
Expiry date	Oct 26, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y302/01035
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to pharmaceutical preparations comprising Factor VIII, a sulfated glycosaminoglycan and a hyaluronidase for the non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders. The invention further relates to the combined use of a Factor VIII, a sulfated glycosaminoglycan and a hyaluronidase for the treatment and prevention of bleeding disorders, and to a method for increasing the bioavailability after non-intravenous administration of Factor VIII by co-administration of a sulfated glycosaminoglycan and a hyaluronidase.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.